Biocon Limited on Tuesday received USFDA approval for its generic version of Liraglutide Injection (18 mg/3 mL), a GLP-1 weight management drug sold under the brand name Saxenda, marking the company’s ...

Biotech firm Biocon Ltd on Tuesday (February 24) announced that it has received approval from the US Food and Drug Administration (USFDA) for its complex formulation Liraglutide Injection, 18 mg/3 mL ...

Abstract: Accurate measurement of bladder volume is critical for the effective management of urinary diseases. Among the available modalities, ultrasound imaging is favored due to its ...

These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics’ existing portfolio of 17 oncology medications, which ...

Biocon Biologics Ltd obtains full exclusive global rights for Hulio, a biosimilar Adalimumab, from Fujifilm Kyowa Kirin Biologics. The deal grants Biocon control over manufacturing and ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. The Viatris stake is one of ...

Viatris (VTRS) on Saturday said that it has entered into definitive agreements with Biocon for the sale of Viatris' equity stake in Biocon Biologics Limited. Under the definitive agreements, Biocon ...

I write about Asia's richest, fast-growing businesses, and startups. Biocon—controlled by Indian pharmaceutical billionaire Kiran Mazumdar-Shaw—is buying the rest of privately held subsidiary Biocon ...

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion. Biocon will ...

Biocon to acquire stakes via share swaps with Serum Institute, Tata Capital, Activ Pine Shreehas Tambe to lead combined entity as CEO, managing director Biocon reviewed IPO, merger options before ...

In a move aimed at expanding affordable treatment options for millions of Americans living with diabetes, Biocon Biologics Ltd. and nonprofit generic drug manufacturer Civica, Inc. have announced a ...